SCHEMBL5604467

SCHEMBL5604467

O=C(c1ccccc1)c1cccc(C(=O)c2ccccc2)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.63
CNR2 P34972 2/20 0.62
ALDH1A1 P00352 3/20 0.59
TDP1 Q9NUW8 2/20 0.58
TSHR P16473 2/20 0.58
KDM4E B2RXH2 1/20 0.58
ALOX15 P16050 1/20 0.58
ACMSD Q8TDX5 1/20 0.58
ATM Q13315 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
MEN1 O00255 3/20 0.52
SRD5A2 P31213 1/20 0.50
POLB P06746 1/20 0.50
NPC1 O15118 1/20 0.48
MAPT P10636 1/20 0.48
PKM P14618 1/20 0.48
HPGD P15428 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PBRM1 Q86U86 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7145613 0.96 KMT2A (0.64) KMT2ACNR2ALDH1A1TDP1TSHR
SCHEMBL10627200 0.86 KMT2A (0.53) KMT2ACNR2ALDH1A1TDP1TSHR
SCHEMBL9828649 0.86 KMT2A (0.53) KMT2ACNR2ALDH1A1TDP1TSHR
SCHEMBL16415854 0.86 KMT2A (0.53) KMT2ACNR2ALDH1A1TDP1TSHR
SCHEMBL27825425 0.86 KMT2A (0.53) KMT2ACNR2ALDH1A1TDP1TSHR
SCHEMBL11454469 0.86 CNR2 (0.58) KMT2ACNR2ALDH1A1TDP1ATM
SCHEMBL11398480 0.82 KMT2A (0.50) KMT2ACNR2ALDH1A1TDP1TSHR
SCHEMBL20412771 0.81 KMT2A (0.68) KMT2ACNR2TDP1KDM4EALOX15
SCHEMBL11064851 0.81 KMT2A (0.49) KMT2ACNR2ALDH1A1TDP1TSHR
SCHEMBL9299025 0.81 CNR2 (0.49) KMT2ACNR2ALDH1A1TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114539341-B Rare earth complex doped DNA crystal for detecting medicine and preparation method and application thereof 青岛大学 2023-12-01 CN claimed
CN-114539341-A Rare earth complex doped DNA crystal for detecting medicine and preparation method and application thereof 青岛大学 2022-05-27 CN claimed
JP-1188526-A None JP disclosed
US-12258358-B1 Ferrocene-substituted organometallic complexes THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-03-25 US disclosed
WO-2024086607-A1 FERROCENE-SUBSTITUTED ORGANOMETALLIC COMPLEXES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-04-25 WO disclosed
CN-114539341-B Rare earth complex doped DNA crystal for detecting medicine and preparation method and application thereof 青岛大学 2023-12-01 CN disclosed
CN-116199621-A Synthesis method of chiral pyridine-2, 6-diol 中国科学院大连化学物理研究所 2023-06-02 CN disclosed
CN-114539341-A Rare earth complex doped DNA crystal for detecting medicine and preparation method and application thereof 青岛大学 2022-05-27 CN disclosed
US-11193082-B2 Wax isomerized oil ENEOS CORPORATION (JP) 2021-12-07 US disclosed
CN-107406546-B Process for producing oligomer and catalyst JXTG能源株式会社 2021-02-19 CN disclosed
US-20210032550-A1 METHOD FOR PRODUCING WAX ISOMERIZED OIL ENEOS CORPORATION (JP) 2021-02-04 US disclosed
WO-2002000339-A2 LIGANDS AND CATALYST SYSTEMS THEREOF FOR ETHYLENE OLIGOMERISATION TO LINEAR ALPHA OLEFINS SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) 2002-01-03 WO disclosed
EP-1125928-A9 TRANSITION METAL COMPOUNDS, CATALYSTS FOR THE PRODUCTION OF ALPHA-OLEFINS AND PROCESS THEREFOR IDEMITSU PETROCHEMICAL CO., LTD. (JP) 2001-11-14 EP disclosed
CN-1321111-A Transition metal catalyst and preparation of polymer of alpha-olefin and vinyl compound IDEMITSU PETROCHEMICAL CO (JP) 2001-11-07 CN disclosed
EP-1136122-A1 TRANSITION METAL CATALYSTS AND PROCESSES FOR PRODUCING $g(a)-OLEFIN AND VINYL COMPOUND POLYMER IDEMITSU PETROCHEMICAL CO., LTD. (JP) 2001-09-26 EP disclosed
EP-1125928-A1 TRANSITION METAL COMPOUNDS, CATALYSTS FOR THE PRODUCTION OF ALPHA-OLEFINS AND PROCESS THEREFOR IDEMITSU PETROCHEMICAL CO., LTD. (JP) 2001-08-22 EP disclosed
WO-2001023396-A1 POLYMERISATION CATALYST BP CHEMICALS LIMITED (GB) 2001-04-05 WO disclosed
WO-2001000686-A1 METHOD FOR COPOLYMERIZING POLAR AND NON-POLAR MONOMERS BAYER AKTIENGESELLSCHAFT (DE) 2001-01-04 WO disclosed
EP-1044992-A1 Catalytic system for the polymerisation of olefin Bayer Aktiengesellschaft (DE) 2000-10-18 EP disclosed
JP-H01188526-A NOVEL POLYCONDENSATION PRODUCT AND PRODUCTION THEREOF N O K SOGO GIJUTSU KENKYUSHO:KK 1989-07-27 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258358-B1 Ferrocene-substituted organometallic complexes FECH, NDUFS4, NDUFS8 KMT2A 2045/4885CNR2 3503/4885ALDH1A1 1836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.